According to a recent LinkedIn post from Beacon Biosignals, the company has collaborated with Idorsia Pharmaceuticals to develop an Insomnia EEG Score (IES) derived from polysomnography data. The post indicates that the model was trained on more than 3,000 overnight EEG studies from roughly 2,100 individuals, positioning it among the largest insomnia neurophysiology datasets reported to date.
The LinkedIn post highlights that IES aims to quantify insomnia severity using distributed EEG patterns rather than traditional single metrics such as total sleep time or wake after sleep onset. Commentary cited in the post suggests the tool is intended to augment diagnosis by stratifying patients, improving clinical trial design, and informing treatment choices.
For investors, the development of IES points to Beacon Biosignals’ growing capabilities in EEG-based biomarker discovery, which could strengthen its positioning as a partner for pharmaceutical companies in central nervous system and sleep-related drug development. The collaboration with Idorsia may also signal commercial interest in using objective neurophysiological measures to optimize insomnia trials, potentially expanding Beacon’s role in clinical research workflows.
If adopted more broadly, an objective insomnia scoring tool could increase demand for Beacon’s analytics platforms and services, supporting recurring revenue tied to clinical trials and research programs. In the longer term, such capabilities may enhance the company’s competitive edge in precision neurophysiology, although the financial impact will depend on the pace of clinical integration and validation in real-world settings.


